Beth Kaufman Zelnick's Insider Trades & SAST Disclosures
Beth Kaufman Zelnick's most recent trade in CorMedix Inc was a trade of 87,500 Common Stock done . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Beth Kaufman Zelnick.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CorMedix Inc | Beth Zelnick Kaufman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 87,500 | 131,456 (0%) | 0% | 0 | Common Stock | |
| CorMedix Inc | Beth Zelnick Kaufman | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.22 per share. | 02 Jan 2025 | 11,844 | 119,612 (0%) | 0% | 8.2 | 97,358 | Common Stock |
| CorMedix Inc | Beth Kaufman Zelnick | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.77 per share. | 16 Dec 2024 | 6,044 | 43,956 (0%) | 0% | 8.8 | 53,006 | Common Stock |
| CorMedix Inc | Beth Zelnick Kaufman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2024 | 12,500 | 62,500 (0%) | 0% | - | Common Stock | |
| CorMedix Inc | Beth Zelnick Kaufman | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2024 | 12,500 | 37,500 | - | - | Restricted Stock Units | |
| CorMedix Inc | Beth Zelnick Kaufman | Chief Legal Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.77 per share. | 12 Dec 2024 | 6,044 | 56,456 (0%) | 0% | 8.8 | 53,006 | Common Stock |
| CorMedix Inc | Kaufman Beth Zelnick | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy Common Stock) | |
| CorMedix Inc | Beth Kaufman Zelnick | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2023 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges